Vendors in the Human Growth Hormone Market are facing tough competition as small and large vendors all attempt to market products that pharmacologically similar.
Further, many new players are entering, on account of the growth opportunity that exists, making competition even more cut-throat.
The Global Human Growth Hormone Market is growing at a rapid pace and is expected to post a CAGR of 4.22 percent from 2015-2019. TechNavio analysts bring you the top 13 companies helping to fuel market growth during the forecast period:
Top 13 Human Growth Hormone Companies in the World
Merck Serono
“Our expertise in both biotechnology and pharmaceutical chemistry, combined with a profound understanding of disease in our focus therapeutic areas, enables us to take a flexible approach to finding the right compound to treat a specific disease. The capability to develop and manufacture new molecular entities of either type with equal success allows Merck Serono to exploit the full potential of the biological and chemical spheres at every stage of the drug development process.
Merck Serono markets Saizen and Serostim for the treatment of growth hormone deficiency. Merck estimates the remaining useful life of Saizen to be 6 years.”
Pfizer
“Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them
Pfizer markets Genotropin, Genotropin MiniQuick, Genotropin Mixer, and Genotropin Pen for the treatment of growth hormone deficiency. For H1 2014, Pfizer reported Genotropin market sales of US$360 million.”
Novo Nordisk
“Novo Nordisk is a focused healthcare company and a world leader in the Growth hormone segment.
In 2013, Novo Nordisk led the Global Human Growth Hormone market, with a 28 percent market share by volume. Currently, Novo Nordisk’s Norditropin is the only marketed prefilled pen-based liquid growth hormone product that remains stable at room temperature. For H1 2014, Norditropin generated market sales of US$539.51 million.”
The US is currently the largest Human Growth Hormone Market in the world, for more information about the Human Growth Hormone Market in the US, please check Technavio’s report Human Growth Hormone Market in the US 2018-2022 or download your FREE Human Growth Hormone Market in the US Sample now!
F. Hoffmann-La Roche
“F. Hoffmann-La Roche markets products such as Nutropin, Nutropin AQ, and Nutropin AQ NuSpin in the Global Human Growth Hormone market. For H1 2014, Nutropin generated market sales of US$121.19 million.
We are known for pharmaceutical medicines since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.”
Anhui Anke Biotechnology (Group)
“We, at Anhui Anke Biotechnology (Group) Co. Ltd. are a leading firm in developing, manufacturing and marketing of pharmaceuticals and health-care products. We are located in China Hefei New and High Technology Development Area.
With a highly efficient Research & Development Center, we have undertaken National 863 Projects, National scientific and technological project and National key Torch Program to name a few. We have also undertaken Scientific and Technological Projects, key scientific and technological specialties of Anhui province and Natural Fund Project. We have developed nearly 10 Novel Drugs in recent years.”
BioPartners
“Biopartners is dedicated to improving quality of life through significant advancements in patient care. We are a dynamic and growing biopharmaceutical company, leading the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology. Our comprehensive product portfolio consists of first-generation biopharmaceuticals with innovative-formulations or novel delivery systems.
Biopharmaceutical company focused on the development, manufacture, and commercialization of products for various therapeutic areas including endocrinology and virology.”
Eli Lilly
“Eli Lilly is focused on discovery, development, manufacture, and commercialization of pharmaceutical products for human and animal use.
For more than 135 years, Lilly has discovered, developed and acquired innovative new medicines that address key unmet medical needs worldwide. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs.”
Ferring Pharmaceuticals
“Freeing is a biopharmaceutical company engaged in the identification, development, and marketing of products across different therapeutic areas such as endocrinology and infertility. The company’s research activities and products are connected by a common focus of providing tailored treatments that work on the body’s own terms, enabling doctors to combat numerous diseases and medical conditions.
Ferring has its own production facilities in several European countries and in South America, Israel and China. It is also currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.”
GeneScience Pharmaceuticals
“GenSci’s production facility is located in one of the top 6 national biomedical centers, Changchun High-Tech Development Zone, GenSci’s manufacturing facility covers more than 20,000 sq.m. of land with 11,000 sq.m. of production area. It is one of the largest and best-equipped biopharmaceutical productions in China. As one of the leading genetic engineering pharmaceutical companies in China, GenSci is also the largest manufacturer of recombinant human growth hormone in Asia.”
Ipsen
“Improving the lives of patients is what drives us. The search for innovative solutions to disabling conditions is at the heart of everything we do. Increased life expectancy is making the pursuit of our inspiring vocation more vital than ever: finding effective therapeutic solutions to cure disease, relieve suffering and bring value to the community.
We aim to be among the top 10 pharmaceutical companies in the world, in terms of growth and profitability. We want to be respected above all for our strategic model, our success, and the commitment of our teams towards patients.”
LG Life Sciences
“Our involvement in pharmaceuticals dates back to 1981, when we began genetic engineering research as a division of LG Chemical.
Since then, we have focused on the development of synthetic and bioengineered drugs, and we have enjoyed noteworthy success. For example, our quinolone antibiotic FACTIVE® became the first-ever new drug developed in Korea to receive FDA approval in 2003. It is now available in the US market and sales are growing steadily.”
Sandoz International
“Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. With a history of more than 120 years, Sandoz is a trusted leader with a reputation for exceptional quality. Our strategic and customer-focused approach to developing, producing and marketing high-quality affordable medicines following the loss of patent protection, has successfully made us one of the two largest and most respected generics companies worldwide.”
Teva Pharmaceutical Industries
“The foundation of our success, and at the heart of Teva, is our vision to be the most indispensable medicines company for the world, executing on our obligation to our patients, customers, shareholders and employees.
Established in 1901, today we rank among the 10 top pharmaceutical companies in the world. Headquartered in Israel, Teva is active in 60 countries, with over 46,400 dedicated employees worldwide.”
View more market report on Cardiovascular and Metabolic Disorders Sectors
